Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
CAV Regimen for R/R Ph- B-ALL
CAV Regimen for R/R AML
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Enrolling by InvitationNCT05509855 ↗
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
RecruitingNCT05334069 ↗
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingNCT05290662 ↗
Registry of Patients Having Received oNKord®
RecruitingNCT05750706 ↗
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
👨⚕️ Marianna Criscuolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2022View details ↗
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
RecruitingNCT05326919 ↗
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingNCT05840575 ↗
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Bright Ideas - CIN Feasibility Study
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →